Pathomechanism of MicroRNA-29 in Shoulder Stiffness

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02534558

Enrollment

Registered

2015-08-27

Start date

2014-08-01

Completion date

2019-07-31

Last updated

2017-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stiffness of Shoulder, Not Elsewhere Classified

Keywords

MicroRNA-29, shoulder stiffness, mir-29a

Brief summary

The team integrates experimental analyses of clinical and basic medicine and transgenic mice models. miR-29a acts a potent protective factor against excessive fibrosis in myofibroblasts of subacromial bursa tissue. Gain of miR-29a stabilizes tendon and synovial tissue homeostasis that alleviates tissue stiffness and maintains function.

Detailed description

Aims of first: The team will evaluate the associations among the mR-29a, miR-29b, miR-29c expression in subacromial bursa and subacromial fluid, incidence of shoulder stiffness, Constant scores, and VAS. Aims of second: The team will isolate primary myofibroblast from subacromial bursa tissue as in vitro models and investigate the molecular events in the IL-1β modulation of miR-29a expression and the molecular mechanism underlying miR-29a inhibition of fibrotic matrix accumulation and apoptotic reactions in myofibroblast cultures.

Interventions

BIOLOGICALmiR 29a

Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Double-blind

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* aged 18 to 80 years * receiving surgery for open acromioplasty

Exclusion criteria

* shoulder disorders caused by traumatic fracture * previous surgery * osteoarthritis * malignant disorders * hepatic disorders * renal disorders

Design outcomes

Primary

Measure	Time frame	Description
The microRNA expression, mRNA expression as a measure	48hr	Differences among incidence, microRNA expression, mRNA expression of shoulder stiffness are analyzed using non-parametric student's t-test. P value of \< 0.05 is considered statistically significant.

Countries

Taiwan

Contacts

Primary ContactJih-Yang Ko, MD

kojy@cgmh.org.tw886-7-731-7123

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026